Explore the Cellular Immunotherapy Program

Overview

The mission of the Mass General Cellular Immunotherapy Program is to invent, develop, administer, and understand engineered immune effector cells. Our approach is to expand cellular engineering and immunotherapy research by bringing together physicians and laboratory scientists focused on immune cell engineering and its clinical effects. We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies, with the ultimate goal of developing curative treatments for cancer and other diseases.

Our objectives:

We aim to enhance the cohesion between biological, translational, and clinical aspects of cell engineering to implement safe and potent immunotherapies.

  • Bring together clinical researchers who administer, manage, and/or investigate immune effector cells as a therapeutic modality
  • Enable translational research and collaboration
  • Optimize immune monitoring and laboratory correlatives of clinical observations
  • Promote cellular therapy education through education sessions
  • Provide high quality care and management of patients receiving cellular therapies
  • Obtain and maintain FACT accreditation for the administration of immune effector cells
  • Invent and develop novel forms of cellular engineering that will become the next generation of immune cell therapies

Clinical Trials

View Cellular Therapy clinical trials.

CAR T-Cell Therapies

Mass General Cancer Center is an authorized treatment center for FDA approved CAR T-cell therapies for adult patients with lymphoma (Breyanzi, Kymriah, Tecartus and Yescarta) and for adult patients with multiple myeloma (Abecma). Learn more.

TIL Therapy for Melanoma

Mass General Cancer Center is one of the first centers nationwide that offers FDA-approved Iovance TIL therapy (lifileucel) for patients with metastatic melanoma. Learn more.

CAR-T Therapy for Glioblastoma: INCIPIENT Clinical Trial

A research team from the Mass General Cancer Center recently conducted an early-stage trial of a new cell therapy for patients with recurrent glioblastoma. Preliminary results have shown remarkable initial responses among the first patients to receive the novel treatment. Learn more about the trial here and here.

If you are interested in learning more about the INCIPIENT clinical trial, please call 617-724-6226 or email carteamingbm@mgb.org. A member of our clinical team will contact you within 48 business hours.


Videos


Resources

Gene and Cell Therapy Institute

Gene and Cell Therapy Institute

Learn how gene and cell therapy research at Mass General Brigham is rapidly advancing.

Maus Lab

Maus Lab

Visit the Maus laboratory, view publications and meet the team.

CAR T-Cell Therapies

CAR T-Cell Therapies

View CAR T-Cell Therapies.

TIL Therapy

TIL Therapy

Mass General is one of the first centers to offer TIL therapy for pts with melanoma.

Severe Immunotherapy Complications Service

Severe Immunotherapy Complications Service

Learn about Mass General's Severe Immunotherapy Complications Service.

Immune Monitoring Lab

Immune Monitoring Lab

Learn about the Immune Monitoring laboratory.

Cellular Therapy & Transplantation Lab

Cellular Therapy & Transplantation Lab

Learn about the Cellular Therapy & Transplantation Laboratory.

FACT Standards

FACT Standards

FACT Standards for Immune Effector Cells.

FACT information

FACT information

The why, what, and how of the new FACT standards for immune effector cells.